Description
The project will focus on the activities required for Phase 3 clinical trials/regulatory approval for their novel antibody treatment (EB05) targeting acute respiratory distress syndrome (ARDS), the most common cause of death in COVID-19 pat…
Amendment chain · 2 entries
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header. For this agreement: $23,000,000 at start, $23,000,000 after amendment #1 (+$0).
- #02022-01-01$23,000,000
- #12025-09-30$23,000,000
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2022-01-01(start date) | $23,000,000 | — | Phase 3 project for EB05 (anti-TLR4 monoclonal antibody) in Hospitalized COVID-19 Patients |
| #1 amendment | 2025-09-30 | $23,000,000 | +$0 | The project will focus on the activities required for Phase 3 clinical trials/regulatory approval for their no… |
Related records · 7
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (business number 815678123)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 033-2020-2021-Q4-513437 | Innovation, Science and Economic Development Canada | Innovation, Sciences et Développement économique Canada · SIF Stream 1 - R&D | $14,053,500 | FY2021 |
| 172-2020-2021-Q1-950033 | National Research Council Canada | Conseil national de recherches Canada · Innovation Assistance Program | $81,312 | FY2021 |
Other recipients funded under "SIF Stream 1- R&D" by Innovation, Science and Economic Development Canada | Innovation, Sciences et Développement économique Canada (most recent first)
| Ref | Recipient | Fiscal year | Current value | FY |
|---|---|---|---|---|
| 033-2024-2025-Q2-819558 | Coveo Solutions Inc. | FY2025 | $15,170,000 | FY2025 |
| 033-2024-2025-Q2-816194 | Kepler Communications Inc. | FY2025 | $20,000,000 | FY2025 |
| 033-2024-2025-Q2-819803 | Pratt & Whitney Canada Corporation | FY2025 | $11,322,000 | FY2025 |
| 033-2024-2025-Q1-820045 | Biotechnologies Aramis Inc. | FY2025 | $40,000,000 | FY2025 |
| 033-2024-2025-Q1-819661 | Giatec Scientific Inc. | FY2023 | $17,500,000 | FY2023 |
Cite as: Glassbox record view · Federal grants & contributions · 033-2023-2024-Q3-514239 · retrieved 2026-11-12.